| Literature DB >> 23723968 |
Aranka Anema1, Keith Chan, Yalin Chen, Sheri Weiser, Julio S G Montaner, Robert S Hogg.
Abstract
OBJECTIVES: Little is known about the potential impact of food insecurity on mortality among people living with HIV/AIDS. We examined the potential relationship between food insecurity and all-cause mortality among HIV-positive injection drug users (IDU) initiating antiretroviral therapy (ART) across British Columbia (BC).Entities:
Mesh:
Substances:
Year: 2013 PMID: 23723968 PMCID: PMC3664561 DOI: 10.1371/journal.pone.0061277
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics among HIV-positive injection drug users initiating antiretroviral therapy across British Columbia, by food security status, between June 1998 and Sept 2011 (n = 254).
| Characteristic | TotalN (%) | Food Insecure181 (71.3%) | Food Secure73 (28.7%) |
|
|
| ||||
| Median, IQR1 | 38.0 (34.0–43.0) | 38.0 (34.0–43.0) | 38.0 (34.0–43.0) | 0.933 |
|
| ||||
| Male | 211 (83.1%) | 148 (81.8%) | 63 (86.3%) | 0.492 |
| Female | 43 (16.9%) | 33 18.2%) | 10 (13.7%) | |
|
| ||||
| Yes | 58 (22.9%) | 45 (25.0%) | 13 (17.8%) | 0.286 |
| No | 195 (77.1%) | 135 (75.0%) | 60 (82.2%) | |
|
| ||||
| Yes | 28 (11.8%) | 21 (12.2%) | 7 (10.8%) | 0.936 |
| No | 209 (88.2%) | 151 (87.8%) | 58 (89.2%) | |
|
| ||||
| ≥High school | 161 (64.7%) | 110 (61.5%) | 51 (72.9%) | 0.122 |
| <High school | 88 (35.3%) | 69 (38.5%) | 19 (27.1%) | |
|
| ||||
| >$15,000 | 63 (28.1%) | 23 (14.7%) | 40 (58.8%) | <0.001 |
| ≤$15,000 | 161 (71.9%) | 133 (85.3%) | 28 (41.2%) | |
|
| ||||
| ≥18.5 kg/m2 | 219 (96.9%) | 153 (96.2%) | 66 (98.5%) | 0.629 |
| <18.5 kg/m2 | 7 (3.1%) | 6 (3.8%) | 1 (1.5%) | |
|
| ||||
| Yes | 63 (24.8%) | 44 (24.3%) | 19 (26.0%) | 0.899 |
| No | 191 (75.2%) | 137 (75.7%) | 54 (74.0%) | |
|
| ||||
| Median, IQR1 | 1997 (1995–1998) | 1997 (1996–1998) | 1996 (1994–1998) | 0.015 |
|
| ||||
| Yes | 191 (75.2%) | 138 (76.2%) | 53 (72.6%) | 0.655 |
| No | 63 (24.8%) | 43 (23.8%) | 20 (27.4%) | |
|
| ||||
| Yes | 154 (60.6%) | 101 (55.8%) | 53 (72.6%) | 0.019 |
| No | 100 (39.4%) | 80 (44.2%) | 20 (27.4%) | |
|
| ||||
| ≥95% | 123 (48.4%) | 82 (45.3%) | 41 (56.2%) | 0.153 |
| <95% | 131 (51.6%) | 99 (54.7%) | 32 (43.8%) | |
|
| ||||
| Median, IQR1 | 380 (220–510) | 360 (210–500) | 400 (230–555) | 0.149 |
|
| ||||
| Median, IQR1 | 2.6 (2.6–3.7) | 2.6 (2.6–3.8) | 2.6 (2.6–3.2) | 0.250 |
|
| ||||
| Yes | 105 (41.3%) | 87 (48.1%) | 18 (24.7%) | 0.001 |
| No | 149 (58.7%) | 94 (51.9%) | 55 (75.3%) | |
Inter-quartile range
Highly active antiretroviral therapy use
Protease Inhibitor-based regimen
Within last 12 months of interview
Unadjusted and adjusted factors associated with all-cause mortality among HIV-positive injection drug users initiating highly active antiretroviral therapy in British Columbia, between June 1998 and Sept 2011 (n = 254).
| Characteristic | Unadjusted modelHZ1 (95% CI)2 | Adjusted model including food insecurityAHZ3 (95% CI)2 | Adjusted model including hungerAHZ3 (95% CI)2 |
|
| |||
| Yes vs. no | 2.41 (1.45–4.01) | 1.95 (1.07–3.53) | – |
|
| |||
| Yes vs. no | 1.78 (1.21–2.61) | – | 1.05 (0.65–1.70) |
|
| |||
| Per 10 year increase | 1.19 (0.94–1.50) | 1.27 (0.98–1.65) | 1.46 (1.09–1.94) |
|
| |||
| Male vs. female | 0.64 (0.41–1.01) | – | 0.59 (0.34–1.02) |
|
| |||
| Yes vs. no | 1.92 (1.27–2.92) | 2.15 (1.34–3.45) | – |
|
| |||
| Yes vs. no | 1.50 (0.87–2.60) | – | 0.92 (0.46–1.82) |
|
| |||
| >High school vs. ≤high school | 0.85 (0.57–1.25) | – | – |
|
| |||
| >$15,000 vs. ≤$15,000 | 0.27 (0.14–0.50) | 0.33 (0.16–0.68) | 0.28 (0.14–0.58) |
|
| |||
| Yes vs. no | 0.95 (0.61–1.49) | – | – |
|
| |||
| ≥18.5 kg/m2 vs. <18.5 kg/m2 | 0.74 (0.27–2.01) | – | – |
|
| |||
| Per year increase | 1.03 (0.93–1.14) | 0.88 (0.78–1.00) | 0.93 (0.81–1.06) |
|
| |||
| Yes vs. no | 1.21 (0.76–1.93) | – | – |
|
| |||
| Yes vs. no | 0.69 (0.47–1.01) | – | – |
|
| |||
| ≥95% vs. <95% | 0.59 (0.40–0.87) | – | 0.77 (0.48–1.22) |
|
| |||
| Per 100 increase | 0.89 (0.82–0.98) | 0.96 (0.87–1.06) | 0.96 (0.86–1.07) |
|
| |||
| Per Log10 increase | 1.50 (1.23–1.84) | 1.42 (1.12–1.80) | 1.36 (1.05–1.75) |
Hazard Ratio
95% Confidence Interval
Adjusted Hazard Ratio
Highly active antiretroviral therapy
Protease Inhibitor
Within the last 12 months of interview
Figure 1Adjusted cumulative incidence of all-cause mortality among HIV-positive injection drug users initiating antiretroviral therapy in British Columbia, stratified by food security status.
Figure 2Adjusted cumulative incidence of all-cause mortality among HIV-positive injection drug users initiating antiretroviral therapy in British Columbia, stratified by hunger status.